Short-Term Ultramicronized Palmitoylethanolamide Therapy in Patients with Myasthenia Gravis: a Pilot Study to Possible Future Implications of Treatment
Open-label, no control groupHumans
- Design
- Open-label, no control group
- Subjects
- 22 patients with myasthenia gravis
- Dose used in the study
- Ultramicronised PEA 600 mg twice a day for one week, added to usual treatment
- Duration
- 3 weeks of weekly assessments around a 1-week treatment period
- What was measured
- Quantitative myasthenia gravis score; repetitive nerve stimulation of the masseter and axillary nerves; acetylcholine receptor antibody titre
What the authors reported
The clinical score improved (p = 0.034) and the decremental response on masseter nerve stimulation lessened (p = 0.018) during treatment. Antibody titres did not change. The authors note the response was rapid and reversible.
Limits of this study
Open pilot with each patient as their own control, 22 patients, one week of treatment. No placebo, so expectation cannot be excluded for the clinical score; the nerve stimulation measure is more objective.
Source
PubMed 30706796 · doi:10.2174/1871527318666190131121827
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.